

Inpatient Antibigram 2023- Urine Source only

Gram Negative-Urine Only	Aminoglycosides			Beta lactam/Beta lactam inhibitors			Carbapenems		Cephalosporin Class				Fluoroquinolones		Folate pathway inhibitor	Fosfomycin	Monobactams	Nitrofurans		
	Amikacin	Gentamicin	Tobramycin	Amoxicillin/Clavulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Meropenem	Cefazolin	Cefazolin Urine	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfa <small>(Trimethoprim/Sulfamethoxazole)</small>	Fosfomycin	Aztreonam	Nitrofurantoin
Organisms																				
Citrobacter freundii complex (34)		97	97	0	0	0	79	100	100	0			76	73	88	91	97			94
Enterobacter cloacae complex (37)		100	100	0	0	0	78	94	97	0			75	75	97	97	94			29
Escherichia coli (1328)		94	94	90	61	66	98	100	100		97		99	99	76	85	82			98
Escherichia coli, ESBL (132)		68	65				100	97	99					8	23	46	95			90
Klebsiella oxytoca (1)*		100	100	100	0	0	100	100	100	0			100	100	0	100	100			100
Klebsiella pneumoniae (214)		99	99	98	0	88	96	99	100		98		100	100	92	94	95			48
Proteus mirabilis (182)		95	92	96	83	92	99	98	100		93		98	97	79	79	86			0
Pseudomonas aeruginosa (109)	100	98	100				98		93		97		97		81	79		84		
Citrobacter koseri (36)		100	100	100	0	97	100	100	100	91			100	100	97	100	100			75
Klebsiella aerogenes (39)		100	100	0	0	0	76	97	100	0			76	76	92	97	100			41
Klebsiella oxytoca/Raoultella ornithinolytica (59)		96	98	93	0	50	94	100	98	27			96	93	93	98	94			96
Klebsiella pneumoniae ESBL (20)*		65	50				100	100	100					15	30	5				25
Klebsiella variicola (19)*		100	100	100	0	84	94	100	100	94			100	100	94	94	94			78
Morganella morganii (28)*		96	96	0	0	25	92	100	100	0			75	82	71	75	89			0

Cefazolin predicts results for the oral agents-Cefaclor, cefdinir, cefpodoxime, ceftazidime, cefuroxime axetil and loracarbef when used for therapy of uncomplicated UTI's due to E. coli, K. pneumoniae, and P. mirabilis.
***A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only. Interpret with caution.**

COMMENTS:

- Data are obtained from MIC and disk diffusion testing methods.
- Isolate counts are in parenthesis to the right of the organism name.
- MRSA (Methicillin Resistant Staph aureus):In 2023, 183 out 556 (32.9%) Staph aureus were MRSA.
Prior years were as follows: 2022-30%, 2021-30.3%, 2020-30.0%, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014-52.5%.
- ESBL (Extended Spectrum Beta Lactamases): In 2023, 292 out of 3,279 (8.9%) were ESBL (combined inpatient and outpatient).
Prior years were as follows: 2022-8.5%, 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
- Penicillin Resistant Streptococcus pneumoniae: In 2023 no Penicillin Resistant Streptococcus pneumoniae.
Prior year were as follows: 2022, 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Inpatient Antibigram 2023- Urine Source only

Gram positive-Urine only			Ansamysins	Beta lactam/Beta lactam inhibitors	Cephalosprin Class	Fluoroquinolones	Folate pathway inhibitor	Glycopeptides	Lipopeptides	Nitrofurans	oxazolidinones				
	Organisms	Tetracycline	Doxycycline	Rifampin	Ampicillin	Oxacillin	Cefazolin	Levofloxacin	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Vancomycin	Daptomycin	Nitrofurantoin	Linezolid	Penicillin	Ceftriaxone
Enterococcus faecalis (223)	26			99			91		100		99	98			
Enterococcus faecium (15)*	60			73			71		100			100			
Staphylococcus epidermidis (36)	77	80	97		52	52	63		100	100	100	100			
Staphylococcus aureus (47)	89	91	100		100	100	85	97	100	100	97	100			
Methicillin resistant Staphylococcus aureus (25)*	56	80	92		0	0	20	92	100	100	100	100			
Streptococcus pneumoniae (1)*							100		100					100	100

*A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only. Interpret with caution.

COMMENTS:

- Data are obtained from MIC and disk diffusion testing methods.
- Isolate counts are in parenthesis to the right of the organism name.
- MRSA (Methicillin Resistant Staph aureus): In 2023, 183 out 556 (32.9%) Staph aureus were MRSA. Prior years were as follows: 2022-30%, 2021-30.3%, 2020-30.0%, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 - 52.5%.
- ESBL (Extended Spectrum Beta Lactamases): In 2023, 292 out of 3,279 (8.9%) were ESBL (combined inpatient and outpatient). Prior years were as follows: 2022-8.5%, 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
- Penicillin Resistant Streptococcus pneumoniae: In 2023 no Penicillin Resistant Streptococcus pneumoniae. Prior year were as follows: 2022, 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Inpatient Antibiogram 2023- Non Urine Source only

Gram Negative -Non-Urine Only	Aminoglycosides			Beta lactam/Beta lactam inhibitors				Carbapenems		Cephalosprin Class			Fluoroquinolones		Folate pathway inhibitor	Monobactams	
	Amikacin	Gentamicin	Tobramycin	Amoxicillin/Clavulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Meropenem	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Aztreonam
Organisms																	
Citrobacter freundii complex (41)		95	97	0	0	0	80	100	100	0		78	75	80	82	90	
Enterobacter cloacae complex (64)		100	100	0	0	0	82	93	98	0		79	79	95	95	92	100
Escherichia coli (1471)		94	95	90	62	67	98	100	100	83		99	99	77	85	82	
Escherichia coli, ESBL (146)		69	66				100	97	99	0				8	23	46	
Klebsiella oxytoca (1)*		100	100	100	0	0	100	100	100	0		100	100	0	100	100	
Klebsiella pneumoniae (267)		99	99	98	0	89	96	99	100	92		100	100	93	95	95	
Proteus mirabilis (222)		94	92	95	81	91	99	99		2		98	97	79	80	85	
Pseudomonas aeruginosa (192)	100	99	98				95		95		95			81	79		85
Citrobacter koseri (43)		100	100	100	0	93	100	100	100	86		100	100	97	100	97	
Klebsiella aerogenes (50)		100	100	0	0	0	80	98	100	0		80	80	96	98	100	
Klebsiella oxytoca/Raoultella ornithinolytica (95)		97	98	93	0	49	95	100	98	26		97	94	95	98	96	
Klebsiella pneumoniae ESBL (22)*		63	47					100	100					15	31	5	
Klebsiella variicola (25)*		100	100	100	0	88	96	96	100	92		100	96	92	96	96	
Morganella morganii (39)		94	92	0	0	25	94	100	100	0		79	84	74	76	84	

*A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only. Interpret with caution.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. MRSA (Methicillin Resistant Staph aureus): In 2023, 183 out of 556 (32.9%) Staph aureus were MRSA. Prior years were as follows: 2022-30%, 2021-30.3%, 2020-30.0%, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.
4. ESBL (Extended Spectrum Beta Lactamases): In 2023, 292 out of 3,279 (8.9%) were ESBL (combined inpatient and outpatient). Prior years were as follows: 2022-8.5%, 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicillin Resistant Streptococcus pneumoniae: In 2023 no Penicillin Resistant Streptococcus pneumoniae. Prior year were as follows: 2022, 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Inpatient Antibigram 2023-Non Urine Source only

Gram positive- Non Urine Only																		
	Tetracycline	Doxycycline	Gentamicin Synergy Screen	Rifampin	Ampicillin	Penicillin	Oxacillin	Cefazolin	Ceftaroline	Ceftriaxone	Ciprofloxacin	Levofloxacin	Vancomycin	Clindamycin	Daptomycin	Linezolid	Trimethoprim/Sulfa (Trimethoprim/Sulfamethoxazole)	Folate inhibitor
Organisms																		
Enterococcus faecalis (75)			82		100	100					100	98			91	100		
Enterococcus faecium (15)*			100		64							100			100	100		
Staphylococcus epidermidis (69)	81	83		96			42	45			66	63	100	57	100	95		
Staphylococcus aureus (270)	95	98		100		100	99	99				86	100	75	100	99	94	
Methicillin Resistant Staphylococcus aureus (139)	82	97		97			0	0	96			29	100	65	100	100	89	
Streptococcus pneumoniae (16)*						100				100		100	100	87				

*A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only. Interpret with caution.

COMMENTS:

- Data are obtained from MIC and disk diffusion testing methods.
- Isolate counts are in parenthesis to the right of the organism name.
- MRSA (Methicillin Resistant Staph aureus): In 2023, 183 out 556 (32.9%) Staph aureus were MRSA. Prior years were as follows: 2022-30%, 2021-30.3%, 2020-30.0%, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 - 52.5%.
- ESBL (Extended Spectrum Beta Lactamases): In 2023, 292 out of 3,279 (8.9%) were ESBL (combined inpatient and outpatient). Prior years were as follows: 2022-8.5%, 2021-7.8%, 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
- Penicillin Resistant Streptococcus pneumoniae: In 2023 no Penicillin Resistant Streptococcus pneumoniae. Prior year were as follows: 2022, 2021 and 2020-No Penicillin Resistant Streptococcus pneumoniae, 2019- 1 out of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.